Documented histopathology or cytopathology of metastatic prostate adenocarcinoma
Confirmed castration-resistant status, defined as disease progression despite castrate levels of serum testosterone (\<50 ng/dL or \<1.7 nmol/L), as demonstrated by radiographic progression, PSA progression, or symptomatic progression
Prior exposure to an NHA in earlier settings.
Planned or prior initiation of Olaparib + Abiraterone in the 1st line mCRPC setting as per routine clinical practice.
Patients who are willing and able to sign an informed consent and are either currently receiving or are planned to initiate Olaparib + Abiraterone per routine clinical practice.
You may not be if
-Prior exposure to a Poly (ADP-ribose) Polymerase Inhibitor (PARPi), including Olaparib, Rucaparib, Niraparib, or Talazoparib.
Patients who received or progressed on abiraterone in previous lines of treatment before mCRPC diagnosis (e.g., in metastatic hormone-sensitive prostate cancer \[mHSPC\]).
Participation in an investigational clinical trial with another prostate cancer therapy within 30 days prior to Olaparib initiation.
Life expectancy \<3 months (unrelated to mCRPC) that could interfere with study outcomes
Known hypersensitivity to Olaparib, Abiraterone, or their excipients.
Uncontrolled medical conditions that may compromise participation or data interpretation, in the opinion of the Investigator (e.g., severe hepatic impairment, active infections).
Any psychiatric or cognitive conditions that may interfere with the patient's ability to consent or comply with study procedures.
